Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Bramante S, et al. Among authors: vassilev l. Int J Cancer. 2014 Aug 1;135(3):720-30. doi: 10.1002/ijc.28696. Epub 2014 Jan 10. Int J Cancer. 2014. PMID: 24374597 Free article.
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S, Kaufmann JK, Veckman V, Liikanen I, Nettelbeck DM, Hemminki O, Vassilev L, Cerullo V, Oksanen M, Heiskanen R, Joensuu T, Kanerva A, Pesonen S, Matikainen S, Vähä-Koskela M, Koski A, Hemminki A. Bramante S, et al. Among authors: vassilev l. Int J Cancer. 2015 Oct 1;137(7):1775-83. doi: 10.1002/ijc.29536. Epub 2015 Apr 11. Int J Cancer. 2015. PMID: 25821063 Free article.
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.
Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jaderberg M, Priha P, Vassilev L, Vuolanto A, Pesonen S. Ranki T, et al. Among authors: vassilev l. Oncoimmunology. 2014 Dec 15;3(10):e958937. doi: 10.4161/21624011.2014.958937. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941579 Free PMC article.
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Vassilev L, et al. Oncoimmunology. 2015 Apr 1;4(7):e1017702. doi: 10.1080/2162402X.2015.1017702. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140248 Free PMC article.
Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.
Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, Joensuu T, Lundin J, Hemminki A. Taipale K, et al. Among authors: vassilev l. Mol Ther. 2016 Feb;24(1):175-83. doi: 10.1038/mt.2015.143. Epub 2015 Aug 27. Mol Ther. 2016. PMID: 26310629 Free PMC article.
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T. Ranki T, et al. Among authors: vassilev l. J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016. J Immunother Cancer. 2016. PMID: 26981247 Free PMC article.
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Kuryk L, Vassilev L, Ranki T, Hemminki A, Karioja-Kallio A, Levälampi O, Vuolanto A, Cerullo V, Pesonen S. Kuryk L, et al. Among authors: vassilev l. PLoS One. 2017 Aug 10;12(8):e0182715. doi: 10.1371/journal.pone.0182715. eCollection 2017. PLoS One. 2017. PMID: 28796812 Free PMC article.
104 results